Text Size

Metabolic Aspects of Citrate Anticoagulation in Renal Replacement Therapy

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2011 by Charles University, Czech Republic.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Ministry of Health, Czech Republic
Information provided by:
Charles University, Czech Republic
ClinicalTrials.gov Identifier:
NCT01361581
First received: May 25, 2011
Last updated: May 26, 2011
Last verified: May 2011
History of Changes
  Purpose

Citrate anticoagulation is associated with metabolic side effects which are linked to a portion of citrate reaching systemic circulation. Data on significance of systemic gain of citrate and its relationship to method configuration are missing. Patient might also receive certain dose of lactate as a buffer and a dose of glucose if acid-citrate-dextrose solution is used. The authors test variable methods of indirect estimate of systemic dose of citrate which would allow to quantify the metabolic input without mostly unavailable measurements of citrate levels.


Condition
Acute Renal Failure
Critical Illness

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Metabolic Aspects of Citrate Anticoagulation in Renal Replacement Therapy

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Charles University, Czech Republic:

Biospecimen Retention:   Samples Without DNA

frozen plasma


Estimated Enrollment: 120
Study Start Date: January 2008
Groups/Cohorts
ACD (acid-citrate-dextrose)
4% trisodium citrate
unfractionated heparin (UFH)

  Eligibility

Ages Eligible for Study:   16 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

critically ill intensive care patients

Criteria

Inclusion Criteria:

  • Acute renal failure on continuous renal replacement therapy for more than 24 hours (CVVH or CVVHDF).

Exclusion Criteria:

  • Absence of consent.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01361581

Locations
Czech Republic
Dept of Anaesthesia and Intensive Care, General University Hospital, 1st Medical Faculty, Charles University Recruiting
Prague 2, Czech Republic, 120 00
Contact: Martin Balik, A/Prof         martin.balik@post.cz    
Principal Investigator: Martin Balik, MD, PhD            
Sponsors and Collaborators
Charles University, Czech Republic
Ministry of Health, Czech Republic
  More Information

No publications provided

Responsible Party: Martin Balik, A/Prof., MD, PhD, EDIC, 1st Medical Faculty, Charles University, Prague
ClinicalTrials.gov Identifier: NCT01361581     History of Changes
Other Study ID Numbers: NS/10014-4
Study First Received: May 25, 2011
Last Updated: May 26, 2011
Health Authority: Czech Republic: Ethics Committee

Keywords provided by Charles University, Czech Republic:
Acute renal failure
Anticoagulation
Citrate
 Haemodiafiltration
Haemofiltration
Renal replacement therapy

Additional relevant MeSH terms:
Critical Illness
Acute Kidney Injury
Renal Insufficiency
Disease Attributes
Pathologic Processes
Kidney Diseases
Urologic Diseases
 Citric Acid
Anticoagulants
Hematologic Agents
Therapeutic Uses
Pharmacologic Actions
Chelating Agents
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on June 18, 2013